Breaking News Headlines Today | Ground News

Cyber Week Sale - Get 40% off Vantage

curetoday.com image

News from curetoday.com

We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.

curetoday.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about curetoday.com

Where is curetoday.com located?curetoday.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top curetoday.com News

New Trial Shows Major Survival Gains with Epcoritamab Added to Standard R2 Therapy

New Trial Shows Major Survival Gains with Epcoritamab Added to Standard R2 Therapy

67% Center coverage: 3 sources

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.See the Story

Chemotherapy-Based Conditioning Matches Outcomes of Total Body Irradiation for MRD-Negative B-ALL

Chemotherapy-Based Conditioning Matches Outcomes of Total Body Irradiation for MRD-Negative B-ALL

100% Center coverage: 3 sources

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation.See the Story

Fixed-Duration or Continuous Therapy in CLL: Trial Says Take Your Pick

Fixed-Duration or Continuous Therapy in CLL: Trial Says Take Your Pick

100% Center coverage: 1 sources

(MedPage Today) -- ORLANDO -- A year of combination therapy for previously untreated chronic lymphocytic leukemia (CLL) patients led to similar outcomes compared with indefinite BTK inhibition with ibrutinib (Imbruvica) alone, an interim analysis...See the Story

Breaking News Topics Related to curetoday.com